Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study - Ter Haar, N M; van Dijkhuizen, EH P; Swart, J F (Arthritis Rheumatol, 2019)
et al.